Colorectal Cancer
Copyright ©2007 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Mar 14, 2007; 13(10): 1528-1533
Published online Mar 14, 2007. doi: 10.3748/wjg.v13.i10.1528
Stool-based DNA testing, a new noninvasive method for colorectal cancer screening, the first report from Iran
Mohammad Reza Abbaszadegan, Alireza Tavasoli, Arash Velayati, Hamid Reza Sima, Hassan Vosooghinia, Mehdi Farzadnia, Hamid Asadzedeh, Mehran Gholamin, Ezzat Dadkhah, Azadeh Aarabi
Mohammad Reza Abbaszadegan, Arash Velayati, Hamid Asadzedeh, Mehran Gholamin, Ezzat Dadkhah, Azadeh Aarabi, Division of Human Genetics, Immunology Research Center, Bu-Ali Research Institute, MUMS, Mashhad, Iran
Alireza Tavasoli, Department of Surgery, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran
Hamid Reza Sima, Department of Internal Medicine, Imam Reza Hospital, MUMS, Mashhad, Iran
Hassan Vosooghinia, Department of Internal Medicine, Ghaem Hospital, MUMS, Mashhad, Iran
Mehdi Farzadnia, Department of Pathology, Imam Reza Hospital, MUMS, Mashhad, Iran
Author contributions: All authors contributed equally to the work.
Supported by a grant from the vice chancellor for research at Mashhad University of Medical Sciences, NO. 84082
Correspondence to: MR Abbaszadegan, PhD, Director, Division of Human Genetics, Bu-Ali Research Institute, Mashhad University of Medical Sciences, Bu-Ali square, postal code: 9196773117, Mashhad, Iran. abbaszadegan@ams.ac.ir
Telephone: +98-511-7112343 Fax: +98-511-7112343
Received: November 20, 2006
Revised: December 18, 2006
Accepted: January 30, 2007
Published online: March 14, 2007
Abstract

AIM: To detect tumor-associated DNA changes in stool samples among Iranian patients with colorectal cancer (CRC) compared to healthy individuals using BAT-26, p16 hypermethylation and long DNA markers.

METHODS: Stool DNA was isolated from 45 subjects including 25 CRC patients and 20 healthy individuals using a new, fast and easy extraction method. Long DNA associated with tumor was detected using polymerase chain reaction method. Microsatellite studies were performed utilizing denaturating polyacrylamide gel to determine the instability of BAT-26. Methylation status of p16 promoter was analyzed using methylation-specific PCR (MSP).

RESULTS: The results showed a significant difference in existence of long DNA (16 in patients vs 1 in controls, P < 0.001) and p16 (5 in patients vs none in controls, P = 0.043) in the stool samples of two groups. Long DNA was detected in 64% of CRC patients; whereas just one of the healthy individuals was positive for Long DNA. p16 methylation was found in 20% of patients and in none of healthy individuals. Instability of BAT-26 was not detected in any of stool samples.

CONCLUSION: We could detect colorectal cancer related genetic alterations by analyzing stool DNA with a sensitivity of 64% and 20% and a specificity of 95% and 100% for Long DNA and p16 respectively. A non-invasive molecular stool-based DNA testing can provide a screening strategy in high-risk individuals. However, additional testing on more samples is necessary from Iranian subjects to determine the exact specificity and sensitivity of these markers.

Keywords: Stool DNA; Colorectal cancer; Cancer screening; Long DNA; BAT-26; p16